Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells.
about
Recent Developments in Active Tumor Targeted Multifunctional Nanoparticles for Combination Chemotherapy in Cancer Treatment and ImagingNucleic Acid Aptamers: An Emerging Tool for Biotechnology and Biomedical SensingPolymer nanoparticles for drug and small silencing RNA delivery to treat cancers of different phenotypesCo-development of diagnostic vectors to support targeted therapies and theranostics: essential tools in personalized cancer therapyNanotechnology applications in urology: a reviewCancer nanotechnology: emerging role of gold nanoconjugatesTargeted therapy using nanotechnology: focus on cancerSmart functional nucleic acid chimeras: enabling tissue specific RNA targeting therapyDevelopment of Cell-SELEX Technology and Its Application in Cancer Diagnosis and TherapyTherapeutic aptamers: developmental potential as anticancer drugsPolymeric nanoparticles for targeted treatment in oncology: current insightsDesign of ProCAs (protein-based Gd(3+) MRI contrast agents) with high dose efficiency and capability for molecular imaging of cancer biomarkersNovel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitroHER2 targeted molecular MR imaging using a de novo designed protein contrast agentNovel MUC1 aptamer selectively delivers cytotoxic agent to cancer cells in vitroTargeted delivery of chemotherapy agents using a liver cancer-specific aptamerThe use of sensitive chemical antibodies for diagnosis: detection of low levels of EpCAM in breast cancerPSMA ligand conjugated PCL-PEG polymeric micelles targeted to prostate cancer cellsInhibition of cell proliferation by an anti-EGFR aptamerVirus-Inspired Membrane Encapsulation of DNA Nanostructures To AchieveIn VivoStabilityMagnetic Nanoparticle Facilitated Drug Delivery for Cancer Therapy with Targeted and Image-Guided ApproachesNanoparticles as Theranostic Vehicles in Experimental and Clinical Applications-Focus on Prostate and Breast Cancer.A Microfluidic Love-Wave Biosensing Device for PSA Detection Based on an Aptamer Beacon Probe.Nanoparticles for Improving Cancer Diagnosis.Characterization of enhanced monovalent and bivalent thrombin DNA aptamer binding using single molecule force spectroscopy.Drug delivery systems in urology--getting "smarter".Synthesis of size-tunable polymeric nanoparticles enabled by 3D hydrodynamic flow focusing in single-layer microchannelsUltra-high throughput synthesis of nanoparticles with homogeneous size distribution using a coaxial turbulent jet mixerSelection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cellsNanotechnology-based drug delivery for cancer.Deconvolution of a complex target using DNA aptamers.Selective delivery of therapeutic agents for the diagnosis and treatment of cancer.Multitasking by multivalent circular DNA aptamers.Core-controlled polymorphism in virus-like particlesLANTCET: elimination of solid tumor cells with photothermal bubbles generated around clusters of gold nanoparticles.Single-step surface functionalization of polymeric nanoparticles for targeted drug delivery.Photothermal bubbles as optical scattering probes for imaging living cells.Selective targeting of nanocarriers to neutrophils and monocytes.Aptamers: from bench side research towards patented molecules with therapeutic applications.Red blood cell-mimicking synthetic biomaterial particles.
P2860
Q26778234-DF29E4E0-9E08-4DCD-9C85-E54C8A0682BFQ26825644-19400A95-480C-4FF3-A33D-C4396456B731Q26830537-66D1B971-893D-4BEA-BEF8-EA6278DB01E6Q27005742-A03EF130-01AC-4859-9BFC-8693432B1950Q27009446-38542A45-4BE2-4701-9F8D-E01693D0BC01Q27021820-A87D91BB-FBA9-4123-8260-D4DBDC43149BQ27023361-ACABEDFF-EC02-4A8C-8DDC-8392C65F36CDQ27025832-9490B91C-E82D-4071-815D-D3BF18CC09D2Q28080168-715419DA-CC7C-4538-AADC-8262EF64CE7AQ28085157-4ADFE981-B6C7-4FBB-A462-B85C563E14FEQ28087243-8EB53AE9-4212-41B0-888A-8605EE18C5CDQ28235682-5A0F4F34-CB20-411D-9216-2B4AAE91A158Q28476756-B8CA323A-05C4-4B19-AE87-2F399C1D4022Q28477503-65E384AE-3B9E-4557-964D-0254559CA273Q28481099-5F60B69A-3AFA-4499-98FA-949B82D7E61EQ28482911-DBDBD27A-C84D-4A32-98CD-34A9F0F06EB6Q28486906-C45C9278-1823-45EE-B854-960F1ACE3561Q28544848-E1096364-B75E-4C0B-BAEE-726092760CDFQ28743866-9F689728-05F8-4B9B-89C4-07D4A857BE68Q29041378-A069F692-9482-4B80-A2DF-99D49C27E6A1Q30354223-5559C7EF-4BC3-4365-9B25-D64331A91D46Q30354652-5D3B69F2-8F31-4B21-8DC2-52A4B461C2D6Q30406488-88C19260-78DD-4EFB-B842-4034BA644F50Q30442412-3506F244-B3CB-4952-A689-1CD7FB1EE9ABQ30462677-D8B54872-3D50-4903-A712-166AD50CCD05Q30478170-145A4409-B004-48B8-9B65-E6C21400531BQ30501637-2EB6647F-ABB2-4C23-A129-E82AE9364D12Q30581724-BEE39F31-732C-4C43-B2B6-51C4BDC7B51CQ30859838-00C094AE-E047-4E38-93EA-3A0EDF16C726Q33219919-2073977C-9DC7-4FBB-8EE8-03193A06F8F5Q33221136-C975A49A-80D5-475E-9B68-9E2E9C2A06D2Q33230098-005781C0-CAF4-4494-BFCB-0420F17838BCQ33234113-CE58245C-8270-4B6B-8D8E-378EF15A662BQ33269435-F6CBA5B8-8BC7-4B65-97D8-91CBA5216807Q33371962-B8AA7356-37BA-44A2-BFF6-AF7EA9246D60Q33385557-B5B3A6E0-8210-4039-A71C-87E0FC3B2BC4Q33386198-3979F231-2C55-42E6-8046-EA5AC9377EBAQ33433964-9E2727AD-BBC0-4F76-B69B-3657D26A8CBAQ33512089-E184AFF2-4652-4BCD-9E31-CB67230237CAQ33564678-4BEC7F32-6E33-4F08-9299-0C7F0E7FFEDE
P2860
Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells.
@en
type
label
Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells.
@en
prefLabel
Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells.
@en
P2093
P50
P1433
P1476
Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells.
@en
P2093
Robert Langer
Sangyong Jon
Thanh-Nga T Tran
P304
P356
10.1158/0008-5472.CAN-04-2550
P407
P577
2004-11-01T00:00:00Z